

To: Business Editor

[For Immediate Release]



Lee's Pharmaceutical Holdings Limited
李氏大藥廠控股有限公司

Execution of License, Distribution & Supply Agreement for Zingo[®]
(lidocaine hydrochloride monohydrate) between Powder and
Marathon

[25 November 2013, Hong Kong] **Lee's Pharmaceutical Holdings Limited** ("Lee's Pharm" or the "Group", Stock Code: 950) an integrated research-driven and market-oriented pharmaceutical group in China is pleased to announce that the License, Distribution & Supply Agreement ("Agreement") for Zingo[®] (lidocaine hydrochloride monohydrate) powder intradermal injection system has been executed between Powder Pharmaceuticals, Incorporated ("Powder"), an associated company of the Group, and Marathon Pharmaceuticals, LLC ("Marathon") on 15 November 2013.

According to the Agreement, Marathon is appointed by Powder as the exclusive licensee, distributor, marketer, advertiser, promoter, importer and seller of Zingo[®] in the United States. The Agreement is effective on 15 November 2013 and will remain in effect until 31 December 2023.

Dr. Benjamin Li, Chief Executive Officer of the Group and Powder, said, "The signing is an affirmation of Zingo[®]'s market potential. The collaboration with Marathon to market Zingo[®] in the United States symbolizes a breakthrough for Lee's Pharm to gain access to the largest pharmaceutical market in the world. Looking ahead, Lee's Pharm and its subsidiaries will continue to dedicate to the biopharmaceutical technology development and pursue global cooperation with accomplished partners and organizations, striving to expand the reach of its products to other territories beyond China to address unmet medical need."

- End -

About Zingo®

Zingo® (lidocaine hydrochloride monohydrate) is an amide local anesthetic indicated for use on intact skin to provide local analgesia prior to venipuncture or peripheral intravenous cannulation in children 3–18 years of age and to provide topical local analgesia prior to venipuncture in adults. The rapid onset of analgesia in 1-3 minutes provides care givers and patients the opportunity for a pain-free and needle-free access procedure. Clinical trials have shown a statistical difference in pain scores during needle access procedures when using Zingo® versus a placebo system. Zingo® is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type. It is not to be used around the eyes or on body orifices, mucous membranes, or on areas with a compromised skin barrier. Zingo® should only be used on skin locations where an adequate seal can be maintained. Adverse reactions in clinical studies of Zingo® primarily included application-site reactions (i.e., hypoaesthesia, burning, and venipuncture site hemorrhage) and dizziness (which occurred in 0.9% of active treated subjects vs. 0.7% of those administered placebo). Additional information can be found at http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022114s001lbl.pdf.

About Powder Pharmaceuticals, Incorporated (“Powder”)

Powder is an associated company of Lee’s Pharmaceutical Holdings Limited based in Hong Kong and is developing products that utilize a proprietary needleless, painless, powder delivery technology. Powder intends to supply Zingo® globally through international business partners. Powder has successfully obtained approval from U.S. FDA in July 2013 for the manufacturing facilities in Hong Kong to produce Zingo® and market the product to U.S.

About Marathon Pharmaceuticals, LLC (“Marathon”)

Marathon Pharmaceuticals, LLC is a leader in the development, manufacturing and commercialization of specialty pharmaceutical drugs to treat rare diseases for high need patient populations. Marathon is a rapidly growing U.S. based company and has multiple marketed products to complement its early and late stage clinical development programs. Marathon is headquartered in Northbrook, Illinois. Additional information about Marathon is available at www.marathonpharma.com.

About Lee's Pharmaceutical Holdings Limited (“Lee's Pharm”)

Lee's Pharm is a research-based Hong Kong biopharmaceutical company listed in Hong Kong with over 19 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's Pharm focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee's Pharm development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The

mission of Lee's Pharm is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life.

Additional information about Lee's Pharm is available at www.leespharm.com.

This press release is issued by **Porda Havas International Finance Communications Group** for and on behalf of **Lee's Pharmaceutical Holdings Limited**. For further information, please contact:

Porda Havas International Finance Communications Group

Ms. Keely Chan	+852 3150 6760	keely.chan@pordahavas.com
Ms. Cherry Cheung	+852 3150 6773	cherry.cheung@pordahavas.com
Ms. Ka Wai Li	+852 3150 6715	kawai.li@pordahavas.com
Ms. Mandy Zhang	+852 3150 6765	mandy.zhang@pordahavas.com

Lee's Pharmaceutical Holdings Limited

Tel: +852 2314 1282

Email: info@leespharm.com